Potential inhibitory effects of l-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis

Rejuvenation Research

Volumn 16, Issue 6, 2013, Pages 460-466

  Fukami, Kei ^a   Yamagishi, Sho Ichi ^a   Sakai, Kazuko ^a   Kaida, Yusuke ^a   Adachi, Takeki ^a   Ando, Ryotaro ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALANINE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; CARNITINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE; BIOACCUMULATION; BLEEDING; CARNITINE DEFICIENCY; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENITAL BLEEDING; HAIR LOSS; HEART DEATH; HEMODIALYSIS; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHUNT BLEEDING; SIDE EFFECT; SUPPLEMENTATION; THIRST; TREATMENT REFUSAL; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; CARNITINE; DIETARY SUPPLEMENTS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 84890523125     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2013.1459     Document Type: Article

References (33)

1. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
2. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991;266:11649-11653.
3. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991;266:11654-11660.
4. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, Saito A, Kurokawa K, van Ypersele de Strihou C. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: Carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349-2356.
5. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-842.
6. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997;46(Suppl 2):S19-S25.
7. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Yamada S, Takeuchi M, Fukami K, Ueda S, Adachi H, Matsui T, Okuda S, Yamagishi S. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism 2009;58:1624-1628.
8. Yamagishi S. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial 2009;13:534-539.
9. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI, Berg TJ, Hanssen KF, Laakso M. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: A population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005; 25:815-820.
10. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, Laakso M. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: A population-based 18 year follow-up study. Diabetologia 2007;50:1409-1417.
11. Furuya R, Kumagai H, Miyata T, Fukasawa H, Isobe S, Kinoshita N, Hishida A. High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients. Clin Exp Nephrol 2012;16:421-426.
12. Mitome J, Yamamoto H, Saito M, Yokoyama K, Marumo K, Hosoya T. Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients. Calcif Tissue Int 2011;88: 521-529.
13. Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, Bucala R, Yamagishi S. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res 2004;1:39-46.
14. Schupp N, Dette EM, Schmid U, Bahner U, Winkler M, Heidland A, Stopper H. Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients. Naunyn Schmiedebergs Arch Pharmacol 2008;378: 283-291.
15. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, Den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687-3693.
16. Nagano M, Fukami K, Yamagishi S, Sakai K, Kaida Y, Matsumoto T, Hazama T, Tanaka M, Ueda S, Okuda S. Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients. Nephrology (Carlton) 2011;16:299-303.
17. Mulder DJ, Water TV, Lutgers HL, Graaff R, Gans RO, Zijlstra F, Smit AJ. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 2006;8:523-535.
18. Januszewski AS, Sachithanandan N, Karschimkus C, O'Neal DN, Yeung CK, Alkatib N, Jenkins AJ. Non-invasive measures of tissue autofluorescence are increased in type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabet Med 2012;29:726-733.
19. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006;29:2654-2659.
20. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003;42:941-967.
21. Carvajal K, Moreno-Sánchez R. Heart metabolic disturbances in cardiovascular diseases. Arch Med Res 2003;34: 89-99.
22. Ascunce RR, Nayar AC, Phoon CK, Srichai MB. Cardiac magnetic resonance findings in a case of carnitine deficiency. Tex Heart Inst J 2013;40:104-105.
23. Adachi T, Fukami K, Yamagishi S, Kaida Y, Ando R, Sakai K, Adachi H, Otsuka A, Ueda S, Sugi K, Okuda S. Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients. Nephrology (Carlton) 2012;17:689-694.
24. Rajasekar P, Anuradha CV. L-Carnitine inhibits protein glycation in vitro and in vivo: Evidence for a role in diabetic management. Acta Diabetol 2007;44:83-90.
25. Takahashi M, Ueda S, Misaki H, Sugiyama N, Matsumoto K, Matsuo N, Murao S. Carnitine determination by an enzymatic cycling method with carnitine dehydrogenase. Clin Chem 1994;40:817-821.
26. Daugirdas JT. Linear estimates of variable-volume, singlepool Kt/V: An analysis of error. Am J Kidney Dis 1993; 22:267-270.
27. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury. Pharmacol Res 2012;65:297-302.
28. van Es A, Henny FC, Kooistra MP, Lobatto S, Scholte HR. Amelioration of cardiac function by L-carnitine administration in patients on haemodialysis. Contrib Nephrol 1992;98: 28-35.
29. Sayed-Ahmed MM, Khattab MM, Gad MZ, Mostafa N. Lcarnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol Res 2001;44: 235-242.
30. Kuragano T, Kida A, Furuta M, Nanami M, Otaki Y, Hasuike Y, Nonoguchi H, Nakanishi T. The impact of beta2-microglobulin clearance on the risk factors of cardiovascular disease in hemodialysis patients. ASAIO J 2010;56:326-332.
31. Jourde-Chiche N, Dou L, Sabatier F, Calaf R, Cerini C, Robert S, Camoin-Jau L, Charpiot P, Argiles A, Dignat-George F, Brunet P. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. J Thromb Haemost 2009;7:1576-1584.
32. De Simone C, Tzantzoglou S, Famularo G, Moretti S, Paoletti F, Vullo V, Delia S. High dose L-carnitine improves immunologic and metabolic parameters in AIDS patients. Immunopharmacol Immunotoxicol 1993;15:1-12.
33. Akdag I, Yilmaz Y, Kahvecioglu S, Bolca N, Ercan I, Ersoy A, Gullulu M. Clinical value of the malnutrition-inflammationatherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study. Nephron Clin Pract 2008;108:c99-c105